Sarepta Therapeutics Income Statement (2010-2026) | SRPT

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	141.84M	189.41M	111.97M	22.00M	211.20M	207.77M	169.18M	253.50M	22.25M	331.82M	463.53M	413.46M	362.93M	467.17M	658.41M	133.33M	611.09M	399.36M	442.93M	400.29M
Cost of Revenue (Quarter)	19.52M	23.44M	31.74M	31.44M	37.80M	39.95M	30.80M	35.02M	34.12M	37.03M	44.18M	50.56M	44.55M	91.69M	132.30M	137.56M	152.56M	150.78M	398.71M	108.77M
Gross Profit (Quarter)	122.32M	165.96M	80.23M	-9.44M	173.41M	167.82M	138.38M	218.48M	-11.87M	294.79M	419.36M	362.90M	318.39M	375.48M	526.11M	-4.23M	458.53M	248.58M	44.23M	291.52M
Operating items
Amortization - Intangibles (Quarter)	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.44M	0.76M	0.60M	0.60M	0.60M	0.60M	0.60M	0.67M	0.68M	0.68M	0.69M
Research & Development (Quarter)	239.62M	139.12M	197.30M	194.25M	252.33M	216.71M	213.80M	245.68M	241.89M	194.30M	195.52M	200.40M	179.69M	224.48M	199.95M	773.45M	204.39M	218.89M	325.34M	153.96M
Selling, General & Administrative (Quarter)	72.35M	61.13M	78.06M	71.84M	154.32M	104.79M	120.48M	110.71M	118.56M	120.89M	131.70M	127.00M	138.80M	128.20M	163.87M	133.63M	137.90M	91.89M	128.30M	108.95M
Restructuring Costs (Quarter)																		40.50M	1.50M
Other Operating Expenses (Quarter)	102.00M			31.62M				35.20M	102.00M			51.16M				138.16M	153.22M	151.46M	399.38M	109.46M
Operating Expenses (Quarter)	331.66M	223.86M	307.27M	297.71M	444.62M	361.62M	365.26M	391.59M	394.76M	352.66M	372.16M	378.56M	363.63M	444.98M	496.73M	1,045.24M	495.51M	502.75M	854.52M	372.37M
Operating Income (Quarter)	-167.57M	-34.46M	-105.81M	-86.88M	-211.13M	-131.35M	-106.83M	-138.09M	-133.52M	-20.84M	24.62M	34.91M	-0.70M	22.20M	161.68M	-300.39M	115.58M	-103.39M	-411.58M	358.43M
EBIT (Quarter)	-167.57M	-34.46M	-105.81M	-86.88M	-211.13M	-131.35M	-106.83M	-138.09M	-133.52M	-20.84M	24.62M	34.91M	-0.70M	22.20M	161.68M	-300.39M	115.58M	-103.39M	-411.58M	358.43M
Non-operating items
Interest & Investment Income (Quarter)	0.05M	0.15M	0.10M	0.17M	2.41M	4.78M	9.13M
Other Non Operating Income (Quarter)	-0.41M		-60.58M			98.50M		387.30M			-404.64M	6.54M	14.28M	-20.82M		-83.13M	38.06M	138.60M	-157.91M	-15.26M
Non Operating Income (Quarter)	85.81M	-0.31M	-60.58M	-17.27M	-16.96M	0.38M	5.53M	12.71M	16.93M	-12.33M	15.75M	6.54M	14.28M	11.81M	10.06M	-83.13M	38.06M	-90.66M	116.42M	-15.26M
Net income details
EBT (Quarter)	-81.76M	-47.91M	-74.26M	-104.15M	-228.09M	-256.42M	337.27M	-512.71M	-14.59M	-33.17M	279.03M	41.45M	13.58M	34.01M	79.64M	-383.52M	153.64M	-194.05M	-278.30M	343.17M
Tax Provisions (Quarter)	-0.35M	0.24M	0.09M	0.88M	3.39M	1.32M	7.94M	4.04M	9.36M	7.76M	-17.02M	5.30M	7.10M	0.40M	12.94M	63.99M	-43.25M	-14.10M	4.91M	12.21M
Profit After Tax (Quarter)	-81.41M	-48.14M	-121.98M	-105.03M	-231.48M	-257.74M	-109.24M	-516.75M	-23.94M	-40.94M	45.66M	36.12M	6.46M	33.61M	159.05M	-447.51M	196.89M	-50.57M	-412.23M	330.96M
Income from Continuing Operations (Quarter)	-81.41M	-48.14M	-74.35M	-105.03M	-231.48M	-257.74M	329.33M	-516.75M	-23.94M	-40.94M	296.05M	36.15M	6.48M	33.61M	66.69M	-447.51M	196.89M	-179.95M	-283.21M	330.96M
Consolidated Net Income (Quarter)	-81.41M	-48.14M	-74.35M	-105.03M	-231.48M	-257.74M	329.33M	-516.75M	-23.94M	-40.94M	296.05M	36.15M	6.48M	33.61M	66.69M	-447.51M	196.89M	-179.95M	-283.21M	330.96M
Income towards Parent Company (Quarter)	-81.41M	-48.14M	-74.35M	-105.03M	-231.48M	-257.74M	329.33M	-516.75M	-23.94M	-40.94M	296.05M	36.15M	6.48M	33.61M	66.69M	-447.51M	196.89M	-179.95M	-283.21M	330.96M
Net Income towards Common Stockholders (Quarter)	-81.41M	-48.14M	-74.35M	-105.03M	-231.48M	-257.74M	329.33M	-516.75M	-23.94M	-40.94M	45.66M	36.55M	6.80M	34.02M	174.87M	-447.51M	201.19M	-179.95M	-282.85M	350.86M
Additional items
EPS (Basic) (Quarter)	-1.02	-0.60	-1.43	-1.20	-2.65	-2.94	-1.24	-5.86	-0.27	-0.46	0.76	0.38	0.07	0.35	1.65	-4.60	2.01	-0.50	-3.93	3.15
EPS (Weighted Average and Diluted) (Quarter)	-1.02	-0.60	-1.43		-2.65	-2.94	-1.24		-0.27	-0.46	0.76	0.37	0.07	0.34	1.50	-4.60	1.89	-0.50	-3.93	2.88
Shares Outstanding (Weighted Average) (Quarter)	79.75M	0.08M	81.26M	0.09M	87.51M	87.47M	87.56M	88.19M	88.47M	88.61M	92.40M	93.99M	94.31M	94.67M	95.08M	97.36M	98.00M	98.55M	100.12M	104.99M
Shares Outstanding (Diluted Average) (Quarter)									88.74M	88.61M	92.40M		99.14M	99.57M	107.88M		106.62M	98.55M	100.12M
EBITDA (Quarter)	-81.40M	-48.17M	-121.98M	-105.31M	-233.66M	-258.46M	-107.70M	-515.51M	-24.58M	-40.52M	47.21M	34.51M	6.12M	36.89M	161.68M	-300.39M	196.81M	-179.68M	-411.58M	358.43M
Interest Expenses (Quarter)	16.18M	20.65M	16.05M	15.80M	16.96M	14.74M	12.70M
Tax Rate (Quarter)	0.43%	-0.49%	-0.12%	-0.84%	-1.49%	-0.51%	2.35%	-0.79%	-64.14%	-23.40%	-6.10%	12.79%	52.29%	1.18%	16.25%	-16.69%	-28.15%	7.27%	-1.77%	3.56%

Research Tools

Developers

Sarepta Therapeutics Income Statement (2010-2026) | SRPT

Research Tools

Developers

Sarepta Therapeutics Income Statement (2010-2026) | SRPT

Create an account

Sign In

Reset Password